Kornimate/medical-research-clean huggingface dataset:
cervical stabilization in individuals with obstructive sleep apnea

Conditions: Obstructive Sleep Apnea

Summary: this study will be performed in people with obstructive sleep apnea, in which one group will receive treatment with cervical stabilization for six weeks and the control group will receive treatment after the interval of six weeks

the objective of this study was to evaluate the muscle strength of the cervical flexor and extensor muscles, to investigate the presence of cervical dysfunction and temporomandibular dysfunction, as well as to verify the effects of cervical stabilization in individuals with obstructive sleep apnea (osa). the research will be carried out at the orofacial motricity laboratory of the federal university of santa maria (ufsm) and the university hospital of santa maria (husm). men and women between 20 and 60 years of age with a diagnosis of osa will be invited to participate in this study, confirmed by polysomnography. the sample will consist of 22 patients with osa, 11 subjects in the osa group (osa g) and 11 in the control group (cg) randomly. at the initial evaluation, an anamnesis will be performed and participants will respond to the epworth sleepiness scale (ess), pittsburgh sleep quality index (psqi) and stop-bang questionnaire. the craniocervical posture will also be evaluated through photogrammetry (sapo); the presence and severity of temporomandibular dysfunction (tmd) by the instruments diagnostic criteria in research for temporomandibular dysfunction (rdc / tmd) and temporomandibular index (tmt); the presence of cervical dysfunction by the craniocervical dysfunction index (ccid); the pressure pain threshold and the strength of the cervical flexor and extensor muscles, by pressure algometry and dynamometry, respectively. the osa g will be submitted to cervical stabilization using the pressure biofeedback device (stabilizer) and, after six weeks will be reassessed by the same questionnaires and instruments of the initial evaluation. the cg after six weeks will be reevaluated and the same treatment protocol will be offered.

Eligibility criteria:
inclusion criteria: * men and women aged 20 to 60 years; * clinical diagnosis of obstructive apnea of mild, moderate or severe sleep through polysomnography following the apnea / hypopnea index. exclusion criteria: * body mass index (bmi) greater than or equal to 35 kg / m2; * use of continuous positive airway pressure; * diagnosis of neurological or neuromuscular disease; * history of craniocervical trauma; * be under physiotherapeutic or speech-language therapy for, respectively, craniocervical and orofacial motor dysfunction or have performed in the last three months; * being in use of intraoral orthodontic appliances, which produce mandibular advancement

Keywords: physical therapy specialty
remediation of impaired self-regulation in patients with mild tbi

Conditions: Mild Traumatic Brain Injury

Summary: the ability to regulate impulses enables us to plan for the future, to maintain focus in the face of distractions (i.e. to encode memories), and to manage emotions. this self regulation can be compromised in individuals who have a history of mild traumatic brain injury and co-occurring disorders. in this study the investigators are using functional mri scanning to understand how memory and self regulation are expressed in the brains of people with a history of mild traumatic brain injury. the investigators are also testing whether the medication tolcapone may improve memory and self regulation.

in this randomized, double-blind, placebo-controlled, crossover cognitive neuroscience study, the investigators are evaluating whether the comt inhibitor tolcapone impacts memory and self regulation, as measured both behaviorally (via cognitive testing) and neurophysiologically (via functional mri). a new study arm that does not include use of tolcapone, nominally equivalent to the placebo arm only, is now also included to address performance on cognitive testing alone.

Eligibility criteria:
inclusion criteria: * veteran ages 18-50 and in general good health; * able to read english at a 6th grade level; * able to provide written informed consent; * normal or corrected to normal visual acuity; * stable doses of all medications (2 weeks or greater); * history of mild traumatic brain injury greater than 6 months prior to participation exclusion criteria: * contraindications to mri scanning; * inability to complete basic fmri requirements; * history of brain surgery or penetrating brain injury; * uncontrolled blood pressure (low or high); * contraindications to tolcapone use (not required for subjects who participate only in the study arm that does not include study medication); * use of medications or drugs with dopamine-related actions within 30 days; * active substance abuse or dependence; * clinically severe medical illness requiring treatment; * history of psychiatric hospitalization (past 1 year) or suicide attempt (past 5 years); * seizures greater than 4 weeks after tbi event or seizures requiring active treatment; * history of brain tumor, stroke, alzheimer's disease, aneurysm rupture, or multiple sclerosis; * history of schizophrenia, adhd or psychiatric diagnosis except depression or ptsd

Keywords: concussion traumatic brain injury mri memory tolcapone
a study of ro5045337 [rg7112] in patients with hematologic neoplasms.

Conditions: Hematologic Neoplasms

Summary: this study will determine the maximum tolerated dose of ro5045337 and the optimal associated 4 weekly dosing schedule of ro5045337, administered as monotherapy in patients with hematologic neoplasms. a first cohort of patients will receive the starting dose of 20mg/m2/day orally, once daily for 10 days in each 28 day cycle. subsequent cohorts of patients will receive dose escalations, and possible changes in dosing schedule, based on tolerability and pharmacokinetic knowledge gained from prior treatment cohorts. different formulations of ro5045337 will be tested and the food effect evaluated. the anticipated time on study treatment is until disease progression or intolerable toxicity.


Eligibility criteria:
inclusion criteria: * adult patients, \>=18 years of age * acute myeloid leukemia, acute lymphocytic leukemia, chronic myelogenous leukemia in blast phase, refractory chronic lymphocytic leukemia/small cell lymphocytic lymphoma * relapsed or refractory to approved therapies, or no viable alternative therapy available * ecog performance status of 0-2 exclusion criteria: * patients receiving any other agent or therapy to treat their malignancy * pre-existing gastrointestinal disorders which may interfere with absorption of drugs * clinically significant cardiovascular disease * pregnant or lactating women * hiv-positive patients receiving combination antiretroviral therapy * amendment j and onward for patients in the food effect evaluation and for all subsequent patients if dosing with a high fat/high calorie meal is found to be optimal: patients with allergies to any ingredient in the defined liquid supplement and/or inability to tolerate a high fat/high calorie meal twice daily on scheduled ro5045337 dosing days
cervical collar for patients with moderate obstructive sleep apnea

Conditions: Obstructive Sleep Apnea

Summary: this study evaluates treatment effect of cervical collar (cc) in moderate obstructive sleep apnea.the investigators believe that stabilization of the neck by using a cc during sleep helps sustain airway patency. this would mean preventing collapse of airways during sleep. the study is a randomized, open, parallel-group intervention study. the two treatment groups are: a. patients with moderate osa are treated with lifestyle advice (n = 50) b. patients with moderate osa are treated with cc and lifestyle advice (n = 50).

moderate and severe obstructive sleep apnea (osa) is strongly associated with cardiovascular diseases, diabetes and also with occupational and traffic accidents due to fatigue and daytime sleepiness. treatment of moderate osa is usually by a mandibular advancement device (mad) and in sometimes even continuous positive airway pressure (cpap). mad and cpap treatment effectiveness is impeded by limited compliance with long term treatment. knowledge about mechanical barriers in upper respiratory tract has triggered interest in finding a new treatment method that may prevent collapse of airways during sleep. the investigators believe that stabilization of the neck by using a cervical collar (cc) during sleep helps sustain airway patency. this would mean improved oxygen saturation in the blood and a reduction of daytime fatigue in patients with osa.

Eligibility criteria:
inclusion criteria: * moderate obstructive sleep apnea (ahi 15-30) * bmi \<35 * age 18-75 * signed informed consent exclusion criteria: * ongoing or planned pregnancy during intervention * whiplash injury or other neck pain * rheumatic diseases * dementia * active alcohol or drug abuse \<2 back in time * treatment with sleeping pills or other sedatives * cannot wear cc for any reason * pregnant or lactating women * not expected to be able to comply with nighttime breathing registration/treatment due to medical and/or psychological conditions.

Keywords: apnea/hypopnea index
confocal laser micro-endoscopy in chronic obstructive pulmonary disease (copd) and lung transplant recipients

Conditions: Lung Transplantation; Chronic Obstructive Pulmonary Disease

Summary: aspects of confocal laser micro-endoscopy (clme) and morphometry in chronic obstructive pulmonary disease (copd) and lung transplant recipients is described and will be correlated with clinical findings in order to described small airway remodelling in these patients.

in early phases of copd, changes in small airway characteristics may develop. elastin decay and matrix remodelling could be responsible for these changes. using clme changes of in the bronchiolar wall and alveolar ducts can be visualized, described and measured. in lung transplant recipients, cmle will be performed to distinguish characteristics of distal airways in stabile patient in contrast to patients with bronchiolitis obliterans syndrome. in both groups data will be correlated with ct findings, pulmonary function tests and anatomopathological results.

Eligibility criteria:
inclusion criteria: * referral for bronchoscopic investigation/sampling * informed consent signed * recent spirometric data exclusion criteria: * sedated and/or ventilated patients * patients on icu * patients under oral anticoagulation * co-existing lung disease * acute infectious pulmonary disease

Keywords: confocal laser scanning microendoscopy small airways copd lung transplantation
autologous adipose stem cells and platelet rich plasma therapy for patients with knee osteoarthritis

Conditions: Knee Osteoarthritis

Summary: adipose stem cells and platelet rich plasma can regenerate the injured cartilage.

the proposed study is two centers, unblinded, non randomized, phase i/ii trial in which the patients will be treated with a single dose of autologous stromal vascular cells (svf) in combination with platelet rich plasma (prp). this study aimes to evaluate the clinical efficiency of autologous adipose tissue-derived msc transplantation in patients with confirmed osteoarthritis at grade ii and iii. adipose tissue is isolated from the belly, and used for extraction of the svf. the svf is mixed with activated platelet-rich plasma before injection. the clinical efficiencies are evaluated by the pain score (vas), lysholm score, and mri findings. svf is isolated from about 100 ml of adipose tissue, and prp is prepared from 20 ml of peripheral blood. total injection volume will be about 5-10 ml. the total number of svf to be injected is 1.0 x 10(7) to 5 x 10(7).

Eligibility criteria:
inclusion criteria: * age \>18 years and ability to understand the planned treatment. * idiopathic or secondary osteoarthritis of the knee with grade 2, 3 radiographic severity ability and willingness to undergo liposuction exclusion criteria: * pregnant women or cognitively impaired adults. * presence of large meniscal tears ("bucket handle" tears), as detected by clinical examination or by magnetic resonance imaging. * inflammatory or postinfectious arthritis. * more than 5 degrees of varus or valgus deformity. * kellgren lawrence grade 4 osteoarthritis in two compartments (the medial or lateral compartments of the tibiofemoral joint or the patellofemoral compartment) in persons over 60 years of age. * intraarticular corticosteroid injection within the previous 3 months. * a major neurologic deficit. * serious medical illness with a life expectancy of less than 1 year. * prior admission for substance abuse * body mass index (bmi) of 40 kg/m2 or greater * patient receiving experimental medication or participating in another clinical study within 30 days of signing the informed consent * in the opinion of the investigator or the sponsor the patient is unsuitable for cellular therapy

Keywords: adipose stem cell platelet rich plasma knee osteoarthritis injured cartilage
efficacy of the clp® hip - retrospective

Conditions: Osteoarthritis; Avascular Necrosis; Rheumatoid Arthritis

Summary: the purpose of this study is to evaluate the survivorship and efficacy of the encore clp® hip stem in a group of no more than 200 patients from whom data has already been collected.


Eligibility criteria:
inclusion criteria: 1. patients must be 18 years of age or older. 2. noninflammatory degenerative joint disease including * osteoarthritis of the natural femoral head * avascular necrosis of the natural femoral head * rheumatoid arthritis 3. correction of functional deformities 4. femoral fracture 5. patients must be able and willing to complete all study-related visits. exclusion criteria: 1. anyone who is under 18 years of age 2. infection or sepsis 3. insufficient bone quality which may affect the stability of the implant 4. muscular, neurological or vascular deficiencies, which compromise the affected extremity 5. skeletally immature patients and cases where there is a loss of abductor musculature, poor bone stock, poor skin coverage around hip joint which would make the procedure unjustifiable 6. osteomyelitis 7. rapid joint destruction or bone absorption apparent on roentgenogram 8. pathological conditions of the acetabulum which would prevent achieving proper range of motion, appropriate head stability, and/or a well-seated and supported smooth articulation of the head within the acetabulum 9. alcoholism or other addictions 10. materials sensitivity 11. loss of ligamentous structures 12. high levels of physical activity (e.g., competitive sports, heavy physical labor) 13. pregnancy
the analgesic efficacy supra-scapular nerve rf after breast surgery

Conditions: Chronic Pain Syndrome

Summary: eighty patients with chronic shoulder pain after breast surgery were allocated randomly into 2 groups; forty patients received fluoroscopically guided supra-scapular nerve pulsed radiofrequency (prf) followed by injection of 0.25% bupivacaine solution containing 40 mg of methylprednisolone (group1) and forty patients received fluoroscopically guided supra-scapular nerve injection of of 0.25% bupivacaine solution containing 40 mg of methylprednisolone (group 2) without active pulsed radiofrequency only demo mode was applied.

eighty patients with chronic shoulder pain after breast surgery were allocated randomly into 2 groups ; forty patients received fluoroscopically guided supra-scapular nerve pulsed radiofrequency (prf) followed by injection through the radiofrequency needle of 0.25% bupivacaine solution containing 40 mg of methylprednisolone (group1) and forty patients received fluoroscopically guided supra-scapular nerve injection of 0.25% bupivacaine solution containing 40 mg of methylprednisolone (group 2) without active pulsed radiofrequency only demo mode was applied.

Eligibility criteria:
inclusion criteria: * patients with post-mastectomy pain exclusion criteria: * exclusion criteria are patients with any medical contraindications to neurolysis, patients with other bone metastases.

Keywords: post mastectomy pain
surgery treatment of type 2 diabetes mellitus patients with grade 1 obesity and overweight

Conditions: Diabetes Mellitus; Obesity; Overweight

Summary: this study evaluate the duodenal ileal interposition with sleeve gastrectomy for type 2 diabetes mellitus in grade 1 obesity and overweight patients.

a clinical trial, 1-arm treatment (duodenal ileal interposition with sleeve gastrectomy for type 2 diabetes mellitus), including 50 research subjects with type 2 diabetes mellitus and obesity class i or overweight. the main objective is to analyse the effect on glycemic control after 2 years of follow-up.

Eligibility criteria:
inclusion criteria: * documented diagnosis of type 2 diabetes mellitus; * patients of both sexes treated with oral antidiabetic agents and / or insulins, * stable antidiabetic medication in the last 8 weeks prior to selection, if the therapy includes insulin, the mean daily dose should not have been changed by more than 10% in the last 8 weeks; * hba1c\> 7.0%; * age\> 20 years and \<65 years; * body mass index (bmi) of 25 to 35 kg / m²; * agree to sign the consent form; exclusion criteria: * diabetes mellitus type 1 (anti-glutamic acid decarboxylase(gad) positive) or anti-gad negative body with low β-cell function (peptide c after stimulation \<0.5 ng / ml); * recent vascular event (myocardial infarction, coronary angioplasty or encephalic vascular accident in the last 6 months); * malignant neoplasm; * portal hypertension; * difficulty to cooperate with segment; * low ability to understand surgery; * unrealistic expectations of results; * cognitive deficit; * current pregnancy; * moderate or severe mood disorder; severe anxiety; eating disorders (based on substance-related disorders dsm-v criteria); * chemical dependence or alcoholism (based on substance-related disorders dsm-v criteria).

Keywords: diabetes metabolic surgery ileal interposition
ambient lighting during colonoscopy and its effect on adenoma detection rate and eye fatigue

Conditions: Colorectal Cancer Screening; Colon Adenomatous Polyp

Summary: a retrospective and prospective study to determine if the use of ambient lighting during screening colonoscopy is well tolerated and if ambient lighting will help physicians maintain adenoma detection rates while decreasing symptoms of eye strain as the day progresses.

this study is a a single-center study at an independent community-based teaching hospital comparing adenoma detection rate in screening colonoscopies performed in low lighting with those performed with ambient lighting (75-150 lux). all cases included in the study involved adult patients undergoing screening colonoscopy with a participating gastroenterologist. diagnostic colonoscopies, history of colon resection, colorectal cancer, and cases performed in children, pregnant women, and prisoners were excluded from analysis. cases involving gastroenterology fellows were also excluded. retrospective data was collected over a six month period from january 2017 to june 2017, followed by a prospective arm the during the same calendar months the subsequent year (january 2018 to june 2018).

Eligibility criteria:
inclusion criteria: * adults undergoing screening colonoscopy * procedure performed by a participating gastroenterologist exclusion criteria: * any diagnostic colonoscopies * history of colon resection * history of colorectal cancer * children * pregnant women * prisoners * cases involving trainees, including gastroenterology fellows
assessment of serological techniques for screening patients regarding covid-19-covid-ser

Conditions: CoV2 Positive Caregivers

Summary: covid-ser is a prospective multi-center study for the evaluation of diagnostic performance of available serological tests


Eligibility criteria:
inclusion criteria: * seropositive caregivers screened for anti-sars cov2 antibodies during their consultation at the occupational medicine of hcl. * age: ≥ 18 years old * persons having given their written consent and accepting a follow-up every 6 months for 24 months, followed by a final visit at 36 months. * persons affiliated to a social security scheme or beneficiary of such a scheme. exclusion criteria: * pregnant or lactating woman
pilot study on weight loss in guinea bissau

Conditions: Overweight and Obesity; Weight Loss

Summary: the purpose of this study is to test two versions a weight loss program potentially suitable for implementation in africa. a successful method would have widespread application in low-income countries, with the potential to improve world health.

specific aim 1 is to conduct a 3-4 month pilot study randomizing participants to two versions of a weight loss program. the program will be implemented in a convenience sample of overweight and obese adults living in guinea-bissau and measure changes in body weight loss (primary outcome), adherence to program recommendations including recommended food patterns, blood pressure, eating behavior, physical activity and mood (secondary outcomes). the data will be used to refine the weight loss program and conduct power calculations for a future trial. specific aim 2 is to analyze associations between weight loss, participant demographics and program metrics, to explore reasons for differences in weight loss between participants. factors to be tested include participant bmi, gender and age, as well as adherence to meal portion recommendations, use of sugar-sweetened beverages and provided foods, and physical activity.

Eligibility criteria:
inclusion criteria: * men and women who are overweight or obese (bmi ≥25 kg/m2). * want to lose weight, want to enroll in the study and are willing to sign the informed consent form. * anticipate being able to meet the study requirements for food habits and study meetings, and anticipate remaining in bissau for the study duration. * between the ages of 20 to 65 years. * non-pregnant women, and those who do not intend on becoming pregnant during the course of the study. * a doctor or nurse has signed a note approving participant in the weight loss intervention after seeing a copy of the handout with title "instructions for bissau weight loss pilot project", and a copy of his/her approval is given to the research staff. exclusion criteria: * report food allergies or intolerance or health conditions that would prevent consumption of provided and recommended foods. * participation in another concurrent nutrition research study. * if premenopausal (\<55 years of age), they are pregnant or intend to become pregnant during the course of the study, or are not using a birth control method to prevent pregnancy.

Keywords: obese overweight weight loss west africa